Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsSyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteChromosomes, Human, Pair 5Leukemia, MyeloidAzacitidineAnemia, SideroblasticBone MarrowChromosome AberrationsKaryotypingMonosomyThalidomidePreleukemiaMyeloproliferative DisordersMyelodysplastic-Myeloproliferative DiseasesPancytopeniaAnemia, AplasticChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisBone Marrow CellsAcute DiseaseLeukemiaChromosome DeletionTreatment OutcomeGranulocyte Precursor CellsNeoplasms, Second PrimaryBone Marrow DiseasesHematopoietic Stem Cell TransplantationIron OverloadTrisomyAntimetabolites, AntineoplasticCytogeneticsErythrocyte TransfusionHematologic AgentsTransplantation, HomologousHematopoietic Stem CellsChelation TherapySurvival AnalysisAntigens, CD34ErythropoietinBlood TransfusionDown SyndromeMetabolic Syndrome XCytarabineRemission InductionBlast CrisisTransplantation ConditioningBone Marrow ExaminationThrombocytopeniaHematopoiesisMutationBlood Cell CountVidarabineSurvival RateSweet SyndromeIn Situ Hybridization, FluorescenceDisease ProgressionAnemia, MacrocyticGranulocyte Colony-Stimulating FactorHematologic DiseasesChromosomes, Human, Pair 8Antineoplastic AgentsRetrospective StudiesCore Binding Factor Alpha 2 SubunitAnemiaChromosome DisordersHaploinsufficiencyKaryotypeErythroid Precursor CellsTranslocation, GeneticChromosomes, Human, Pair 20Risk FactorsHematologic NeoplasmsPrimary MyelofibrosisIron Chelating AgentsFlow CytometryHematinicsLeukemia, Myelomonocytic, AcuteErythroid CellsBone Marrow TransplantationErythroblastsDNA Modification MethylasesHemoglobinuria, ParoxysmalImmunophenotypingRecurrenceAntilymphocyte SerumBusulfanFatal OutcomeIsochromosomesHLA-DR Serological SubtypesMyeloid Progenitor CellsErythropoiesisRibonucleoprotein, U2 Small NuclearDNA Mutational AnalysisAntineoplastic Combined Chemotherapy ProtocolsThrombocytosis